Zenas Biopharma Inc (ZBIO) financials
Zenas Biopharma revenue and earnings by year
Zenas Biopharma's revenue was $10.0 million in the fiscal year to December 31, 2025, up 100.0% from the year before. Net income was -$378 million, -3777.4% of revenue.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 3 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
| Revenue | 10 | 5 | 50 |
| Revenue growth | 100.0% | -90.0% | — |
| Operating income | -383 | -164 | -37 |
| Operating margin | -3830.6% | -3277.8% | -74.3% |
| Net income | -378 | -157 | -37 |
| Net margin | -3777.4% | -3139.8% | -74.2% |
| Diluted EPS | -$8.44 | -$11.89 | — |
| Free cash flow | -172 | -120 | -31 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open ZBIO in Markets.
See also: ZBIO returns
No forecast, no recommendation. This page describes Zenas Biopharma Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.